TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00485069
Drug: ROP
Normalized name: rOPG
DrugBank: AMGN-0007 (DB06511)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropinirole Hydrochloride monotherapy group (ROP): Patients will receive ROP tablets 3 times daily. In the 4-week Fixed Titration Phase (from Week 0 as Baseline), the dose will start at 0.75 mg/day and will be increased weekly by 0.75 mg/day up to 3.0 mg/day. In the 48-week Flexible Titration and Maintenance Phase, the dose will be increased by 1.5 mg/day at intervals of at least 1 week up to a maximum of 15.0 mg/day. The dose will be maintained at a level without further symptomatic improvement is expected. Concomitant use of L-dopa is prohibited during the study.
Study: NCT00485069
Drug: ROP+L-Dopa
Normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ropinirole Hydrochloride with L-Dopa adjunct therapy group (ROP+L-Dopa): Patients will receive ropinirole hydrochloride (ROP) tablets 3 times daily. In the 4-week Fixed Titration Phase (from Week 0 as Baseline), the dose will start at 0.75 milligrams (mg)/day and will be increased weekly by 0.75 mg/day up to 3.0 mg/day. In the 48-week Flexible Titration and Maintenance Phase, the dose will be increased by 1.5 mg/day at intervals of at least 1 week up to a maximum of 15.0 mg/day. The dose will be maintained at a level without further symptomatic improvement is expected. The dosing regimen of L-dopa remain unchanged from 4 weeks prior to the start of the Screening Phase throughout the study.
Study: NCT02314728
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients who are randomized to receive misoprostol will have 25mcg placed vaginally. Repeated dosing of misoprostol is based on clinical exam and clinical judgment of the provider.
Study: NCT02314728
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients who are randomized to receive oxytocin alone will receive intravenous administration of oxytocin as designated by the hospital protocol. Protocol begins with 2 milliunits of oxytocin that is then titrated over time. Titration is based on clinical exam and clinical judgment of the provider and is continued until there are adequate uterine contractions.
Study: NCT04527042
Drug: Rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: It is determined by the clinician's routine clinical prescription.
Study: NCT01660867
Drug: 0.9% saline + oral dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: nebulized epinephrine + 0.9% saline + dexamethasone =\> nebulized epinephrine + 0.9% saline
Study: NCT02949349
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Provided as 250mg/capsule, dose specific for each arm, orally twice a day, for 24 weeks.
Study: NCT00653393
Drug: Tranylcypromine
Normalized name: Tranylcypromine
DrugBank: Tranylcypromine (DB00752)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets, 10 mg, single-dose
Study: NCT00653393
Drug: Parnate
Normalized name: Parnate
DrugBank: Tranylcypromine (DB00752)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets, 10 mg, single-dose
Study: NCT00119457
Drug: TTP889
Normalized name: TTP889
DrugBank: TTP889 (DB05131)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04041453
Drug: Ivermectin
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin at 600mcg/kg in addition to albendazole will be provided for 1 or 3 days.
Study: NCT04041453
Drug: Albendazole
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole will be provided as an active control or in experimental arms for 1 or 3 days with ivermectin.
Study: NCT03294694
Drug: Ribociclib
Normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Each treatment cycle lasts 28 days. Ribociclib, 1 time per day by mouth for 21 days, followed by 1-week of rest (28-day cycle)
Study: NCT03294694
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Each treatment cycle lasts 28 days. Fulvestrant will be administered during Cycle 1 on days 1 and 15, and then on day 1 of each 28-day cycle thereafter.
Study: NCT01233167
Drug: clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: clopidogrel 75 mg po per day for 12 months
Study: NCT01233167
Drug: clopidogrel and placebo
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: clopidogrel 50mg per day for 3 months,clopidogrel 25mg per day for 3 months,then placebo 75mg per day for 6 months
Study: NCT00003241
Drug: phenylacetate
Normalized name: phenylacetate
DrugBank: (2-BROMOETHYL)(2-'FORMYL-4'-AMINOPHENYL) ACETATE (DB07955)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04602494
Drug: Varenicline
Normalized name: Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: varenicline: 0.5 mg once daily on days 1-3, 0.5 mg twice daily on days 4-7 and starting on day 8, 1 mg twice daily for a total of 12 weeks
Study: NCT03635372
Drug: Alginate
Normalized name: Alginate
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 cc of Alginate peroral
Study: NCT03635372
Drug: Sucralfate
Normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 cc of Sucralfate peroral
Study: NCT03635372
Drug: Hydrotalcite
Normalized name: Hydrotalcite
DrugBank: Hydrotalcite (DB13322)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 cc of Hydrotalcite peroral
Study: NCT03428568
Drug: Nexium
Normalized name: Nexium
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: omeprazole
Study: NCT03428568
Drug: Amoxil
Normalized name: Amoxil
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotic
Study: NCT02253524
Drug: Dimenhydrinate
Normalized name: Dimenhydrinate
DrugBank: Dimenhydrinate (DB00985)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg Dramamine with 5 cc syringe in 150 ml normal saline given as a slow intravenous infusion over 15 minutes
Study: NCT02253524
Drug: Metoclopramide
Normalized name: Metoclopramide
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg Metoclopramide with 5 cc syringe in 150 ml normal saline given as a slow intravenous infusion over 15 minutes
Study: NCT02688933
Drug: HOE901-U300 (Insulin Glargine 300 U/ml)
Normalized name: insulin glargine 300 UNT/ML
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Self-administered by subcutaneous (SC) injection in the morning (between waking up and breakfast) using a pre-filled pen.
Study: NCT02688933
Drug: Lantus (Insulin Glargine 100 U/ml)
Normalized name: insulin glargine 100 UNT/ML [Lantus]
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Self-administered by subcutaneous (SC) injection in the morning (between waking up and breakfast using a pre-filled pen.
Study: NCT02688933
Drug: Mandated back ground therapy
Normalized name: Pep-Back
DrugBank: Date (DB10632)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid insulin analogs: e.g., insulin glulisine, insulin lispro or insulin aspart, used by participant at least 30 days before screening. Mealtime insulin was to be continued during the study and titrated towards protocol specified postprandial glucose targets (130-180 mg/dL).
Study: NCT00535652
Drug: Ertapenem
Normalized name: Ertapenem
DrugBank: Ertapenem (DB00303)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: powder for infusion, 1 gram I.V., single dose over 30 min.
Study: NCT02012725
Drug: Arm 1 MRI with gadolinium
Normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy volunteers will not receive gadolinium
Study: NCT00098241
Drug: Certican
Normalized name: Bordetella pertussis toxoid vaccine, inactivated / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injectable Suspension [Certiva]
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03844776
Drug: Paracetamol
Normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: paracetamol orally
Study: NCT03844776
Drug: Chlorhexidine mouthwash
Normalized name: chlorhexidine Mouthwash
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.2% chlorhexidine mouthwash
Study: NCT02287038
Drug: Atomoxetine 80 MG
Normalized name: atomoxetine 80 MG
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be randomized and assigned by the study investigator into crossover group 1 (Atomoxetine 80mg at Phase I, then placebo at Phase II) or group 2 (placebo at Phase I, then Atomoxetine at Phase II) with both placebo and medication administered through pharmacy. There was a 1-week interval between the two phases.
Study: NCT03724357
Drug: Vaxchora
Normalized name: Vaxchora
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One dose. Approximately 100 mL of cold or room temperature purified bottled water is placed into a clean disposable cup. The contents of the buffer sachet are added to the water and stirred. Then the contents of the active (lyophilized vaccine) sachet are added to the water and stirred for approximately 30 seconds. The reconstituted mixture should be completely ingested within 15 minutes.
Study: NCT04405323
Drug: Lu AG06466
Normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: hard capsules, orally, single doses
Study: NCT04405323
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 and 300 mg, capsules, orally
Study: NCT01623921
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with Celecoxib 200 mg× 2/d + Rosuvastatin 40× 1/d +:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
Study: NCT02249104
Drug: Adapalene/benzoyl peroxide gel, 0.1%/2.5%
DrugBank: Adapalene (DB00210)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical AV therapy
Study: NCT00919633
Drug: interferon alfa-2b
Normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: subcutaneous continuous infusion at one of three doses for 48 weeks
Study: NCT00919633
Drug: peginterferon alfa-2b
Normalized name: Peginterferon alfa-2b
DrugBank: Peginterferon alfa-2b (DB00022)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.5 μg/kg subcutaneous weekly for 48 weeks
Study: NCT00919633
Drug: ribavirin, USP
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All patients will receive oral ribavirin
Study: NCT00564941
Drug: deferasirox
Normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01699724
Drug: sertraline ODT
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg tablet on Day 1 of each period
Study: NCT00652847
Drug: ezetimibe
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ezetimibe 10 mg/day for a six week course of treatment.
Study: NCT00652847
Drug: statins
Normalized name: Endostatins
DrugBank: Endostatin (DB06423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients on statins have their dose doubled for 6 weeks followed by another 6 month observational phase
Study: NCT03374839
Drug: TIL + IL-2 + Nivolumab
Normalized name: IL-2
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The patients will receive Nivolumab (at a dose of 3 mg per kilogram of body weight) every 2 weeks from day0 until week52.~Two TIL (Tumor Infiltrating Lymphocytes) injections will be performed: at week 14 and at week 18.~The TIL injections are systematically followed by subcutaneous injections of Proleukin® (IL-2) at a concentration of 6 million international unit (IU) per day for 5 days.
Study: NCT03117634
Drug: Treat and Extend with Aflibercept 2mg
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Drug treatment regime which allows extension of treatment interval based on disease activity
Study: NCT03117634
Drug: Fixed Dosing with Aflibercept 2mg
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fixed 8 weekly dosing regime throughout the study duration
Study: NCT01919164
Drug: Sprifermin
Normalized name: Sprifermin
DrugBank: Sprifermin (DB12616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received Sprifermin as intra-articular injection.
Study: NCT00458315
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00458315
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00458315
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00458315
Drug: Avastin (Bevacizumab)
Normalized name: Avastin
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03844776
Drug: Amoxicillin 500 Mg
Normalized name: amoxicillin 500 MG
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin 500 orally
Study: NCT00830505
Drug: fluticasone/salmeterol
Normalized name: FLUTICASONE/SALMETEROL
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 2 puffs twice a day for 2 weeks
Study: NCT00830505
Drug: fluticasone
Normalized name: Fluticasone
DrugBank: Fluticasone (DB13867)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 puffs twice a day for 2 weeks
Study: NCT01334424
Drug: propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2-2.5 mg/kg for induction plus or not plus 2 mg/kg.h for maintenance
Study: NCT01935960
Drug: Retinoid 9cUAB30
Normalized name: RETINOID 9CUAB30
DrugBank: 9CUAB30 (DB12316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT03338881
Drug: TAK-659
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-659 tablets.
Study: NCT00062595
Drug: menatetranone (MK4)
Normalized name: menatetrenone
DrugBank: Menatetrenone (DB12148)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02323178
Drug: eltrombopag
Normalized name: Eltrombopag
DrugBank: Eltrombopag (DB06210)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: initial dose of 50 mg once daily, then the dose can be sequentially increased every 2 weeks up to a maximum dose of 300mg/day
Study: NCT00685906
Drug: Levonorgestrel and Ethinyl Estradiol (Nordette®)
Normalized name: estradiol / ethinyl estradiol / levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 tablet taken by mouth once a day for 28 days per cycle
Study: NCT00733187
Drug: ABT-869
Normalized name: ABT-925
DrugBank: ABT-639 (DB15055)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg/kg
Study: NCT00262145
Drug: tea extracts
Normalized name: green tea extract
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04520503
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The dose of propofol required for loss of consciousness and the total induction dose of propofol will be recorded for every patients.
Study: NCT04942769
Drug: Selenium
Normalized name: Selenium
DrugBank: Selenium (DB11135)
Approvals — FDA: no, EMA: no, PMDA: no
Description: selenium 100ug ，take it orally twice daily
Study: NCT02079480
Drug: BMS-986090
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02100839
Drug: AEM-28
Normalized name: AEM-28
DrugBank: AEM-28 (DB17642)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for injection
Study: NCT00018824
Drug: NALTREXONE
Normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01543568
Drug: aflibercept 2.0 mg
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal aflibercept injection 2.0 mg
Study: NCT03844776
Drug: Metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: metronidazole 500 mg orally
Study: NCT01204099
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01204099
Drug: PX-866
Normalized name: PX-102
DrugBank: PX-102 (DB15416)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02079480
Drug: Keyhole limpet hemocyanin
Normalized name: Keyhole limpet hemocyanin
DrugBank: Keyhole limpet hemocyanin (DB05299)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04787887
Drug: Abcertin
Normalized name: Alcortin
DrugBank: Hydrocortisone (DB00741)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 60IU/kg Single Intravenous Administration
Study: NCT00664352
Drug: Mannose-6-Phosphate (Juvidex)
Normalized name: Recombinant human acid alpha-glucosidase optimized for high expression of mannose 6-phosphate
DrugBank: Mannose (DB12907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: * 100µL of 300mM (8.46 mg/100μL) Juvidex will be injected intradermally into each cm2 of one 3cm2 donor site and into the 0.5cm border around the donor site no more than 20 minutes before graft harvest (total dose 750µL). A further 300µL of 300mM (8.46 mg/100μL) Juvidex will be applied topically within 30 minutes of graft harvest and 24 hours after graft harvest.~* 100µL of placebo will be injected intradermally into each cm2 of the other 3cm2 donor site and into the 0.5cm border around the donor site no more than 20 minutes before graft harvest (total dose 750µL). A further 300µL of placebo will be applied topically within 30 minutes of graft harvest and 24 hours after graft harvest.
Study: NCT00664352
Drug: Mannose-6-Phosphate (Juvidex)
Normalized name: Recombinant human acid alpha-glucosidase optimized for high expression of mannose 6-phosphate
DrugBank: Mannose (DB12907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: * 100µL of 600mM(16.93 mg/100μL) Juvidex will be injected intradermally into each cm2 of one 3cm2 donor site and into the 0.5cm border around the donor site no more than 20 minutes before graft harvest (total dose 750µL). A further 300µL of 600mM (16.93 mg/100μL) Juvidex will be applied topically within 30 minutes of graft harvest and 24 hours after graft harvest.~* 100µL of placebo will be injected intradermally into each cm2 of the other 3cm2 donor site and into the 0.5cm border around the donor site no more than 20 minutes before graft harvest (total dose 750µL). A further 300µL of placebo will be applied topically within 30 minutes of graft harvest and 24 hours after graft harvest.
Study: NCT00664352
Drug: Mannose-6-Phosphate (Juvidex)
Normalized name: Recombinant human acid alpha-glucosidase optimized for high expression of mannose 6-phosphate
DrugBank: Mannose (DB12907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: * 300µL of 300mM (8.46 mg/100μL) Juvidex will be applied topically to one 3cm2 donor site within 30 minutes of graft harvest and 24 hours after graft harvest.~* 300µL of placebo will be applied topically to the other 3cm2 donor site within 30 minutes of graft harvest and 24 hours after graft harvest.
Study: NCT00104182
Drug: insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01044225
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: An initial dose of 400 mg/m² IV over 2 hours and followed by a weekly dose of 250 mg/m² over 1 hour.
Study: NCT01044225
Drug: Cilengitide EMD 121974
Normalized name: Emdisterone
DrugBank: Cilengitide (DB11890)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A dose of 2000 mg by IV administration 2 weekly.
Study: NCT02660060
Drug: Pramipexole Dexa Medica
DrugBank: Pramipexole (DB00413)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pramipexole 0.25 tablets produced by PT Dexa Medica for PT Ferron Par Pharmaceuticals as the test drug.
Study: NCT00664352
Drug: Mannose-6-Phophate (Juvidex)
Normalized name: Mannose 6-phosphate
DrugBank: Mannose (DB12907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: * 300µL of 600mM (16.93 mg/100μL) Juvidex will be applied topically to one 3cm2 donor site within 30 minutes of graft harvest and 24 hours after graft harvest.~* 300µL of placebo will be applied topically to the other 3cm2 donor site within 30 minutes of graft harvest and 24 hours after graft harvest.
Study: NCT02660060
Drug: Pramipexole Boehringer Ingelheim Pharma
DrugBank: Pramipexole (DB00413)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pramipexole 0.25 tablets produced by Boehringer Ingelheim Pharma GmbH \& Co.KG for Boehringer Ingelheim International GmbH as the reference drug.
Study: NCT01795794
Drug: omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02262650
Drug: Telmisartan
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02262650
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02154932
Drug: 2 doses 400 microgram misoprostol
Normalized name: misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 doses 400 microgram misoprostol, 3 and 1 hours
Study: NCT02154932
Drug: single dose misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 dose, 1 hours, prior surgery
Study: NCT00405171
Drug: Nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01912820
Drug: quercetin
Normalized name: Quercetin
DrugBank: Quercetin (DB04216)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT00498680
Drug: Sildenafil, Vardenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil 100mg, vardenafil 20mg, combination of both half dosage.
Study: NCT00498680
Drug: Sildenafil
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100mg
Study: NCT00498680
Drug: Vardenafil
Normalized name: Vardenafil
DrugBank: Vardenafil (DB00862)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20mg
Study: NCT00498680
Drug: Sildenafil & Vardenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50mg \& 10 mg
Study: NCT01051921
Drug: CTS-1027
Normalized name: CTS-1027
DrugBank: CTS-1027 (DB08490)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTS-1027 supplied in 5 and 10 mg tablets, 15 mg taken twice daily, for up to 48 weeks